/

AVBP

ArriVent BioPharma, Inc.Closed

16.09−0.37 −2.25%USD

NasdaqGM · as of Oct 13, 16:00 ET · 15m delayAfter hours 16.37 +1.74%

Open

16.28

Prev close

16.46

Day range

15.9516.72

52-week range

11.3635.83

Volume

1.97M2.06×

Mkt cap

793.36M

P/E ttm

—

Fwd P/E

-4.15

EPS ttm

-3.62

Div yield

0.00%

Earnings

—

From 52w high

−55.09%

Price Chart

Yahoo Finance · delayed

AVBPOct 13, 2026O 16.28H 16.72L 15.95C 16.09−0.37 (−2.25%)Vol 1.97M

SMA 5028.20
SMA 20027.18

1Y change −22.87% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AVBP ArriVent BioPharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +6.63%
1 month: −44.52%
3 months: −50.55%
6 months: −41.79%
Year to date: −20.03%
1 year: −23.01%

Valuation & ownership

Market cap: 793.36M
Enterprise value: 420.59M
P/E (ttm): —
Forward P/E: -4.15
PEG ratio: —
Price / book: 2.12
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -3.62
EPS (forward): -3.87
Beta (5y monthly): 1.35
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 49.31M
Float: 32.26M
Short % of float: 18.18%
Short ratio (days): 13.52
Held by insiders: 1.54%
Held by institutions: 98.53%
Avg volume (3m): 954.86K
50-day average: 28.47
200-day average: 27.21
52-week change: −23.01%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 22.5
vs 50-day SMA: −42.95%
vs 200-day SMA: −40.80%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 13.43%
Realised vol (20d, ann.): 233.4%
From 52-week high: −55.09%
From 52-week low: +41.64%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

20.56

+27.75% implied

Low 15.00Median 18.00High 29.00

Recommendation trend

Now11 / 0 / 0
1m ago11 / 0 / 0
2m ago

DES

About ArriVent BioPharma, Inc.

Yahoo Finance profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 77
Headquarters: Newtown Square, PA, United States
Website: arrivent.com
Officers: Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President & CEO
Dr. Stuart Lutzker M.D., Ph.D.

SEAS

Seasonality · AVBP

2024–2026 · monthly returns

Strongest month Oct +13.18%Weakest month Mar −19.39%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	11.8	2.1	0.4	34.8	-2.6	14.8	-14.2	0.8	0.8	-46.9			−20.0%
2025	7.1	-17.3	-21.7	15.0	-0.0	2.4	-10.4	-2.0	-3.5	1.5	22.5	-12.3	−24.5%
2024		-0.0	-17.1	-7.5	17.5	-4.4	18.1	22.1	-12.1	24.9	2.1	-11.1	+23.6%

INSD

Insider Activity · AVBP

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Dec 9, 2025	Hillhouse Investment Management, Ltd.Beneficial Owner of more than 10% of a Class of Security	Sale at price 23.37 per share.	555.6K	$12.98M
Jul 10, 2025	Lachapelle RobinChief Operating Officer	Conversion of Exercise of derivative security at price 2.28 per share.	11.2K	$25.43K
Sep 18, 2024	Lachapelle RobinChief Operating Officer	Conversion of Exercise of derivative security at price 2.28 - 6.24 per share.	27.6K	$90.48K

AVBP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AVBP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ArriVent BioPharma, Inc.

Seasonality · AVBP

Insider Activity · AVBP

Congress Trades · AVBP

Investors Holding AVBP

Investors Holding AVBP

Congress Trades · AVBP

Insider Activity · AVBP

Seasonality · AVBP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About ArriVent BioPharma, Inc.

Financial Snapshot

Earnings & Dividends

News